Selective VEGFR-2 inhibition with ramucirumab does not usually lead to objective responses in HCC28,29 and it is likely that the inhibition of other tivozanib targets, rather than VEGFR-2, is more important in terms of tumour shrinkage. This evidence concerns the gene KDR and neoplasm.